Phaseline

Companies › Price Vision Group

Price Vision Group: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 4 Phase 2; Ophthalmology; next expected readout Jul 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Riboflavin 0.1% with UVA photoactivation (30 minute protocol)
Riboflavin photosensitizer activated by UVA light to induce corneal crosslinking
–Phase 2Corneal NeovascularizationJul 2029
Riboflavin 0.1% and non-pulsed light–Phase 2KeratoconusDec 2030
Riboflavin 0.1% and pulsed light–Phase 2KeratoconusDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04787471Riboflavin 0.1% with UVA photoactivation (30 minute protocol)Phase 2Corneal NeovascularizationOphthalmologyJul 2029
NCT04787471Riboflavin 0.1% with UVA photoactivation (30 minute protocol)Phase 2Corneal NeovascularizationOphthalmologyJul 2029
NCT07841470Riboflavin 0.1% and pulsed lightPhase 2KeratoconusOphthalmologyDec 2030
NCT07841470Riboflavin 0.1% and non-pulsed lightPhase 2KeratoconusOphthalmologyDec 2030

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

NexThera Regenerative Patch Technologies jCyte NovaSight Emmecell

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.